Bright Minds Biosciences (DRUG) Other Operating Expenses (2024 - 2026)
For the quarter ending Q1 2026, Other Operating Expenses fell 4647.28% year-over-year to -$19.6 million, compared with a TTM value of -$19.2 million through Mar 2026, down 4547.28%, and an annual FY2025 reading of $1.4 million, up 34.27% over the prior year.
Bright Minds Biosciences (DRUG) has disclosed Other Operating Expenses for 2 consecutive years, with -$19.6 million as the latest value for Q1 2026.
- Other Operating Expenses reached -$19.6 million in Q1 2026 per DRUG's latest filing, down from $432107.7 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $432107.7 in Q1 2025 and bottomed at -$19.6 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Bright Minds Biosciences | 464.72 Mn | 405.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.65 Mn |
| Dec 31, 2025 | -10.32 Mn |
| Sep 30, 2025 | 13.15 Mn |
| Jun 30, 2025 | -6.38 Mn |
| Mar 31, 2025 | -4.39 Mn |
| Dec 31, 2024 | -771,430.53 |
| Sep 30, 2024 | 230,888.37 |
| Jun 30, 2024 | 512,105.46 |
| Mar 31, 2024 | 306,489.79 |